Area of research
Oncology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Gastric Cancer Management and Outcomes, Colorectal Cancer Treatments and Studies, Cancer Immunotherapy and Biomarkers, and Esophageal Cancer Research and Treatment.
China Liver Cancer Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2024 Edition)
Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study
Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trial
Turning sour into sweet: Lactylation modification as a promising target in cardiovascular health
The Prospective Registry Of MyositIS (PROMIS): II. Temporal shifts in causes of death among patients with idiopathic inflammatory myopathies
Surufatinib in advanced neuroendocrine tumours: Final overall survival from two randomised, double-blind, placebo-controlled phase 3 studies (SANET-ep and SANET-p)
A visualization analysis of research on arterial compression hemostatic devices using VOSviewer and CiteSpace
Electroacupuncture Improves Sepsis‐Induced Acute Gastrointestinal Injury: A Retrospective Propensity Score‐Matched Cohort Study
Fruquintinib in less pretreated patients: Multivariate profile-matching analysis of FRESCO-2 to FRESCO
Pembrolizumab in Patients of Chinese Descent with Microsatellite Instability-high/Mismatch Repair Deficient Advanced Solid Tumors: KEYNOTE-158 Final Analysis
A140 plus mFOLFOX6 compared with cetuximab plus mFOLFOX6 for first-line RAS wild-type metastatic colorectal cancer: A randomized clinical trial
A phase 2 dose expansion study of ZG006, a trispecific T cell engager targeting CD3/DLL3/DLL3, as monotherapy in patients with advanced neuroendocrine carcinoma.
Combination of ZG005 with etoposide and cisplatin (EP) vs. EP as the first-line therapy for advanced neuroendocrine carcinoma: A randomized, multicenter, phase I/II trial.
Anbenitamab in combination with chemotherapy in patients with HER2‐positive gastric or gastroesophageal junction carcinoma who failed previous therapy containing trastuzumab: a multicenter, phase II study (KC‐WISE 01)
Association between the serum albumin-to-creatinine ratio and 28-day all-cause mortality in sepsis: a retrospective cohort study
Surufatinib plus toripalimab in patients with advanced neuroendocrine tumours and neuroendocrine carcinomas: An open-label, single-arm, multi-cohort phase II trial
Chinese expert consensus on sequential surgery following conversion therapy based on combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2024 edition)
Efficacy and safety of surufatinib plus toripalimab, a chemotherapy-free regimen, in patients with advanced gastric/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, or biliary tract cancer
SCT-I10A combined with a bevacizumab biosimilar (SCT510) versus sorafenib in the first-line treatment of advanced hepatocellular carcinoma: A randomized phase 3 trial.
Chinese Expert Consensus on the Whole-Course Management of Hepatocellular Carcinoma (2023 Edition)
Pembrolizumab in patients from China with microsatellite instability-high/mismatch repair deficient tumors: KEYNOTE-158
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial
Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)
Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer
Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study
Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study
Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer
First-line lenvatinib plus pembrolizumab plus chemotherapy versus chemotherapy in advanced/metastatic gastroesophageal adenocarcinoma (LEAP-015): Safety run-in results.